<DOC>
	<DOCNO>NCT01529138</DOCNO>
	<brief_summary>This study do determine high safe dose combination temsirolimus axitinib ; learn side effect drug give together ; determine patient 's disease respond treatment . The combination drug temsirolimus axitinib study unknown whether treatment benefit patient 's cancer . Temsirolimus commercially available approve treatment type kidney cancer . Axitinib test several disease yet commercially available treatment cancer United States . The combination temsirolimus axitinib approve treatment cancer outside clinical trial .</brief_summary>
	<brief_title>Study Axitinib Temsirolimus Solid Tumors</brief_title>
	<detailed_description />
	<mesh_term>Axitinib</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<criteria>Inclusion Criteria/ Patients must histologically confirm nonhematologic malignancy standard curative palliative measure exist longer effective Patients hepatocellular carcinoma need histologic confirmation malignancy follow criterion meet diagnosis : Liver lesions 1 2 cm arterial enhancement washout venous phase CT/MRI Liver lesion ≥ 2 cm arterial enhancement washout venous phase CT/MRI serum alphafeto protein ≥ 200 ng/mL Eastern Cooperative Oncology Group ( ECOG ) Performance Status 0 1 Marrow Organ function requirement : Absolute Neutrophil Count ≥ 1000/mm³ Platelets ≥ 75,000/mm³ Hemoglobin ≥ 9.0 g/dL Total bilirubin ≤ 1.5 x upper limit normal ( ULN ) Alkaline phosphatase ≤ 2.5 x ULN ( ≤ 5 x ULN liver metastasis present ) Aspartate aminotransferase ( AST ) alanine aminotransferase ( ALT ) ≤ 2.5 x ULN ( ≤ 5 x ULN liver metastasis present patient diagnosis hepatocellular carcinoma cholangiocarcinoma ) Creatinine ≤ 1.5 x ULN Urinalysis ≤ 1+ protein dipstick Urine creatinine : protein ratio &lt; 1.0 If urine protein &gt; 1 1+ urine creatinine : protein ratio &gt; 1 , 24 hour urine protein obtain level &lt; 1000 mg patient enrollment . Fasting serum cholesterol ≤ 350 mg/dL Triglycerides ≤1.5 x ULN Life expectancy ≥ 12 week At least 2 week since end prior systemic treatment ( 4 week bevacizumab contain regimen ) , radiotherapy , surgical procedure resolution treatment relate toxicity No evidence uncontrolled hypertension evidence 2 reading &lt; 140/90 measure 1 hour apart . Preexisting hypertension control medication allow No gastrointestinal disorder include active peptic ulcer disease ( within 6 month ) ; active bleeding unrelated malignancy ; melena , hematemesis , hematochezia past 3 month without endoscopicallyproven resolution No cardiovascular history within 12 month include : myocardial infarction ( MI ) , uncontrolled angina , coronary artery bypass graft ( CABG ) , symptomatic congestive heart failure ( CHF ) Women child bear potential must negative pregnancy test Willingness ability comply schedule visit Able ingest oral medication No concurrent use anticipate need potent cytochrome P450 3A4 ( CYP3A4 ) inhibitor CYP3A4 cytochrome P450 1A2 ( CYP1A2 ) inducer</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>Cancer</keyword>
</DOC>